Male breast cancer is a rare disease that have different outcomes in comparison with the same disease in female counterparts. Due to rarity of its occurrence, data available on breast cancer in male population are relatively scarce. The aim of this study was to summarize data available in the SEER (National Cancer Institute Surveillance, Epidemiology, and End Results) program’s database about male breast cancer. SEER incorporates data from 18 cancer registries all over the United States. Data about clinical and epidemiological patterns as well as survival were analyzed and are subsequently presented.
Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2017 Submission) database was used as the data source. Only males diagnosed between 2000-2015 with malignant breast cancer, known age, and microscopic confirmation were included. Relative survival was calculated using Ederer II method. Further data analysis was made using SPSS version 21.
A total of 6790 patients were identified with a median age of 68. White race constituted the majority of cases (81.3%; n = 5519). Incidence rate was 10.2 per million (95% CI 10 – 10.5) with increasing trend over time (annual percent change = 1.9%, p < 0.05). The disease showed slight predilection to occur on the left side (52.3%; n = 3550). Most cases were staged as regional (n = 2974) or localized (n = 3152) at time of diagnosis. The disease was the only primary cancer in 4502 patients (66.3%) and the first of 2 or more primaries in 787 cases (11.6%). It occurred as a second or later multiple primary in remaining cases (22.1%). Median observed survival was 117.2 months with a 5-years and 10-years observed survival of 70.6% (CI: 69.1%-71.9%) and 48.8% (CI: 46.9%-50.6%) respectively. 5-years relative survival was 84% (CI: 82.3%-85.6%) while 10-years relative survival was 71.1% (CI: 68.3%-73.7%).
Male breast cancer is a rare tumor with an incidence rate of 10.2 per million. This tumor is more likely to occur in old age and white race and occurs more on left side. Disease occurred as a second (or later multiple) primary in 22% of cases. 5-years relative survival is 84% with a median survival of 117.2 months.
Mohamed Alaa Gouda.
Has not received any funding.
The author has declared no conflicts of interest.